Evidence map›Paper›PMID 40952471›Full record

ArticleActa neuropathologica2025

Differences and overlaps in TDP-43 pathology of 'pure' LATE-NC compared to LATE-NC coexisting with Alzheimer's disease.

Sandra O Tomé, Klara Gawor, Simona Ospitalieri, Alicja Ronisz, Markus Otto, Christine A F von Arnim, Estifanos Ghebremedhin, Celeste Laureyssen, Kristel Sleegers, Rik Vandenberghe and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  2. Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Review
  5. Digital seed amplification assay for TDP-43 aggregate quantification in CSF.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sandra O ToméLaboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium. sandra.tome@kuleuven.be.
Klara GaworLaboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Simona OspitalieriLaboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Alicja RoniszLaboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Markus OttoDepartment of Neurology, Ulm University, Ulm, Germany.
Christine A F von ArnimDepartment of Geriatrics, University Medical Center Gottingen, Gottingen, Germany.
Estifanos GhebremedhinInstitute of Anatomy, Johann Wolfgang Goethe University, Frankfurt, Germany.
Celeste LaureyssenComplex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Kristel SleegersComplex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences and Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Peter T NelsonSanders-Brown Center On Aging, Division of Neuropathology, Department of Pathology, University of Kentucky, Lexington, KY, USA.
Dietmar Rudolf ThalLaboratory of Neuropathology, Department of Imaging and Pathology and Leuven Brain Institute, KU Leuven, Leuven, Belgium. Dietmar.thal@kuleuven.be.

Funding

Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classificationR01NS118584 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CYKOWSKI, MATTHEW DANIEL, NELSON, PETER T. · 2024 to 2024
$791k
Alzheimer Forschung Initiative 10810Alzheimer's Association 22-AAIIA-963171Alzheimer's Association AARF-24-1300693Boehringer Ingelheim Ulm University BioCenter D.5009BrightFocus Foundation A2022019FDeutsche Forschungsgemeinschaft TH-624-4-1, 4-2, 6-1EU Joint moodmarker 01ED1202AFonds Wetenschappelijk Onderzoek 1225725NFonds Wetenschappelijk Onderzoek G065721NFoundation of the State Baden-Württemberg D.3830German Federal Ministry of Education and Research FTLDc 01GI1007AKU Leuven PDMT2/21/069Niedersächsisches Ministerium für Wissenschaft und Kultur ZN3553NIH HHS R01 NS118584Onderzoeksraad, KU Leuven C14/17/107PreFrontAls 01ED1512Robert-Bosch-Stiftung 32.5.1140.0007.O/MA01
6 · The paper itself

Abstract

Limbic-predominant age-related TDP-43 encephalopathy (LATE) is a common substrate of dementia in the elderly. LATE and Alzheimer's disease (AD) share similar clinical features, and their underlying neuropathological changes-LATE-NC and ADNC-commonly co-occur. However, the histomorphological and molecular features of TDP-43 pathology in LATE-NC with or without coexisting ADNC are not yet well understood. We performed immunohistochemistry in paraffin-embedded tissue from the hippocampus, amygdala, and temporal and frontal cortices of 108 human autopsy cases including 20 cognitively unimpaired controls, 20 AD dementia cases with moderate-high severity of ADNC without LATE-NC (ADNC group), 34 AD dementia cases with LATE-NC (ADNC + LATE-NC group), 17 dementia cases with LATE-NC but no/low ADNC (pure LATE-NC group), and 17 FTLD-TDP Type A cases. We assessed TDP-43 aggregate morphology and composition using antibodies against different TDP-43 epitopes: pS409/410, pS403/pS404, and C- and N-terminal TDP-43. We also investigated nuclear clearance of physiological TDP-43 and cytoplasmic colocalization of TDP-43 and tau proteins. Pure LATE-NC cases were on average 10 years older at death than ADNC + LATE-NC, had less cognitive impairment, higher prevalence of argyrophilic grain disease (AGD) pathology, aging-related tau astrogliopathy (ARTAG), and APOEε2 allele. They also tended to show lower APOEε4 frequencies, but similar frequencies of hippocampal sclerosis and LATE-NC stages. Importantly, LATE-NC predominantly displayed a mesh-like neuritic TDP-43 pattern in the hippocampus, extending from CA1/2 to subiculum. This mesh-like pattern was present in 81% of pure LATE-NC cases and only in 18% of ADNC + LATE-NC. This pattern was also observed in 53% of FTLD-TDP Type A cases. Moreover, the aggregate composition differed in pure LATE-NC and ADNC + LATE-NC, with LATE-NC cases exhibiting increased burdens of several phosphorylated and non-phosphorylated TDP-43 species, while only the pS409/pS410 epitope was significantly associated with ADNC + LATE-NC in the amygdala. Nuclear clearance patterns also tended to differ between pure LATE-NC and ADNC + LATE-NC. Similar to ADNC + LATE-NC, TDP-43 and tau proteinopathies colocalized in pure LATE-NC with comorbid primary age-related tauopathy (PART) or low ADNC. These data suggest that LATE-NC tends to be modified in the presence of moderate-high ADNC. These differences may reflect upstream influences (age, genetics, and environmental risk factors), direct protein-protein interactions, and/or other impacts of ADNC-related mechanisms on TDP-43 proteinopathy, potentially relevant for clinical trial design and future therapeutic applications.

Indexed as

Alzheimer DiseaseBrainDNA-Binding ProteinsTDP-43 ProteinopathiesAgedAged, 80 and overDementiaFemaleHumansMaleMiddle AgedDNA-Binding ProteinsTARDBP protein, humanAlzheimer’s diseaseLATE-NCLimbic-predominant age-related TDP-43 encephalopathyNeuropathology

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.